Direct thrombin inhibitors' potential efficacy in Alzheimer's disease

American Journal of Alzheimer's Disease and other Dementias

Volumn 27, Issue 8, 2012, Pages 564-567

  Rami, Bou Khalil ^a  

^a SAINT JOSEPH UNIVERSITY   (Lebanon)

Author keywords

Alzheimer's disease; endothelial dysfunction; thrombin; thrombin inhibitors

Indexed keywords

ANTIVITAMIN K; CERTOPARIN; CYTOKINE; DABIGATRAN; DABIGATRAN ETEXILATE; GLYCOPROTEIN P INHIBITOR; GROWTH FACTOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; OLIGOSACCHARIDE; THROMBIN; THROMBIN INHIBITOR;

ALZHEIMER DISEASE; ANGIOGENESIS; ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CELL ACTIVATION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFICACY; ENDOTHELIUM CELL; HUMAN; HYPOXIA; INTERNATIONAL NORMALIZED RATIO; NONHUMAN; OXIDATIVE STRESS; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

EID: 84869007805     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317512465667     Document Type: Review

References (31)

1. Formichi P, Parnetti L, Radi E, Cevenini G, Dotti MT, Federico A. CSF biomarkers profile in CADASIL-A model of pure vascular dementia: usefulness in differential diagnosis in the dementia disorder. Int J Alzheimers Dis. 2010; 2010: 959257
2. Grammas P. Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. J Neuroinflammation. 2011; 8: 26
3. Salmina AB, Inzhutova AI, Malinovskaya NA, Petrova MM. Endothelial dysfunction and repair in Alzheimer-type neurodegeneration: neuronal and glial control. J Alzheimer Dis. 2010; 22 (1). 17-36
4. Humpel C. Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease?. Exp Gerontol. 2011; 46 (4). 225-232
5. Moser KV, Humpel C. Blood-derived serum albumin contributes to neurodegeneration via astroglial stress fiber formation. Pharmacology. 2007; 80 (4). 286-292 (Pubitemid 47557263)
6. Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology. 2004; 23 (4). 159-169 (Pubitemid 38980441)
7. Yin X, Wright J, Wall T, Grammas P. Brain endothelial cells synthesize neurotoxic thrombin in Alzheimer's disease. Am J Pathol. 2010; 176 (4). 1600-1606
8. Grammas P, Samany PG, Thirumangalakudi L. Thrombin and inflammatory proteins are elevated in Alzheimer's disease microvessels: implications for disease pathogenesis. J Alzheimers Dis. 2006; 9 (1). 51-58
9. Arai T, Guo JP, McGeer PL. Proteolysis of non-phosphorylated and phosphorylated tau by thrombin. J Biol Chem. 2005; 280 (7). 5145-5153 (Pubitemid 40279984)
10. Arai T, Miklossy J, Klegeris A, Guo JP, McGeer PL. Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J Neuropathol Exp Neurol. 2006; 65 (1). 19-25
11. Reimann-Philipp U, Ovase R, Weigel PH, Grammas P. Mechanisms of cell death in primary cortical neurons and PC12 cells. J Neurosci Res. 2001; 64 (6). 654-660 (Pubitemid 32520688)
12. Akiyama H, Ikeda K, Kondo H, McGeer PL. Thrombin accumulation in patients with Alzheimer's disease. Neurosci Lett. 1992; 146 (2). 152-154
13. Mhatre M, Nguyen A, Kashani S, Pham T, Adesina A, Grammas P. Thrombin, a mediator of neurotoxicity and memory impairment. Neurobiol Aging. 2004; 25 (6). 783-793 (Pubitemid 38698252)
14. Park KW, Jin BK. Thrombin-induced oxidative stress contributes to the death of hippocampal neurons: role of neuronal NADPH oxidase. J Neurosci Res. 2008; 86 (5). 1053-1063 (Pubitemid 351441303)
15. Huang CF, Li G, Ma R, Sun SG, Chen JG. Thrombin-induced microglial activation contributes to the degeneration of nigral dopaminergic neurons in vivo. Neurosci Bull. 2008; 24 (2). 66-72 (Pubitemid 351738280)
16. Tulinsky A. Molecular interactions of thrombin. Semin Thromb Hemost. 1996; 22 (2). 117-124 (Pubitemid 26239903)
17. O'Brien PJ, Mureebe L. Direct thrombin inhibitors. J Cardiovasc Pharmacol Ther. 2012; 17 (1). 5-11
18. Santini V. A general practice trial of Ateroid 200 in 8,776 patients with chronic senile cerebral insufficiency. Mod Probl Pharmacopsychiatry. 1989; 23: 95-100
19. Lorens SA, Guschwan M, Hata N, van de Kar LD, Walenga JM, Fareed J. Behavioral, endocrine, and neurochemical effects of sulfomucopolysaccharide treatment in the aged Fischer 344 male rat. Sem Thromb Hemost. 1991; 17 (suppl 2). S164 - S173
20. Walzer M, Lorens S, Hejna M, et al. Low molecular weight glycosaminoglycan blockade of betaamyloid induced neuropathology. Eur J Pharmacol. 2002; 445 (3). 211-220 (Pubitemid 34655678)
21. Dudas B, Cornelli U, Lee JM, et al. Oral and subcutaneous administration of the glycosaminoglycan C3 attenuates Abeta(25-35)-induced abnormal tau protein immunoreactivity in rat brain. Neurobiol Aging. 2002; 23 (1). 97-104 (Pubitemid 34066540)
22. Esmon CT. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. J Exp Med. 2002; 196 (5). 561-564 (Pubitemid 35024435)
23. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombinindependent inhibitors. Circulation. 1998; 97 (6). 544-552 (Pubitemid 28090683)
24. Bates SM, Weitz JI.. The mechanism of action of thrombin inhibitors. J Invasive Cardiol. 2000; 12 (suppl F). 27F - 32F
25. Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J. 2008; 29 (2). 155-165
26. Tripodi A, Palareti G. New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation. J Intern Med. 2012; 271 (6). 554-565
27. Schulman S, Kearon C, Kakkar AK, et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361 (24). 2342-2352
28. Schulman S. Treatment of venous thromboembolism with dabigatran. Curr Opin Pulm Med. 2012; 18 (5). 410-415
29. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361 (12). 1139-1151
30. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L.. Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010; 363 (19). 1875-1876
31. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012; 366 (9). 864-866